AIQ Solutions has developed a clinical decision support platform based upon advanced analytics, including artificial intelligence, to address spatial and temporal heterogeneity of disease. Our patented technology automatically detects and quantifies disease burden over time to help researchers better understand the disease and clinicians more precisely treat patients.
Just as not all patients respond the same to any given therapy, not all disease sites within a given patient respond the same. For example, having as few as 5% of tumors not respond to therapy can result in significantly higher mortality. Thus, physicians need to be able to identify and quantitatively track each disease site separately—which is nearly impossible with current technology.
For pharmaceutical companies, our technology dramatically reduces the cost of drug development clinical trials by enabling smaller, faster studies. Our first customer is one of the world’s largest pharmaceutical companies.
For individual patients, our technology reduces healthcare costs and improves outcomes by enabling the care team to better and more quickly adjust therapy based on treatment response.
The Founders and Leaders of AIQ Solutions bring decades of experience leading drug and imaging biomarker development, redefining endpoints to move beyond precision medicine.